Patents by Inventor Lars Ronnstrand

Lars Ronnstrand has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isolated nucleic acid encoding receptor-like TGF-.beta.1 binding protein
    Patent number: 5731200
    Abstract: The invention relates to a family of substantially pure, receptor like TGF-.beta.1 binding glycoproteins. These molecules are characterized by molecular masses of 160 kd, 70-80 kd, and 30-40 kd as determined by SDS-PAGE, and the ability to bind the TGF-.beta.1 molecule. This family of molecules is useful in identifying and/or quantifying TGF-.beta.1 in a sample, as well as inhibiting its effect on cells. Also described are nucleic acid sequences which code for the protein monomer making up the molecules.
    Type: Grant
    Filed: December 5, 1995
    Date of Patent: March 24, 1998
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Hidenori Ichijo, Kohei Miyazono, Lars Ronnstrand, Ulf Hellman, Christer Wernstedt, Carl-Henrik Heldin
  • Substantially pure receptor like TFG-.beta.1 binding molecules
    Patent number: 5578703
    Abstract: The invention relates to a family of substantially pure, receptor like TGF-.beta.1 binding glycoproteins. These molecules are characterized by molecular masses of 160 kd, 70-80 kd, and 30-40 kd as determined by SDS-PAGE, and the ability to bind the TGF-.beta.1 molecule. This family of molecules is useful in identifying and/or quantifying TGF-.beta.1 in a sample, as well as inhibiting its effect on cells. Also described are nucleic acid sequences which code for the protein monomer making up the molecules.
    Type: Grant
    Filed: April 22, 1994
    Date of Patent: November 26, 1996
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Hidenori Ichijo, Kohei Miyazono, Lars Ronnstrand, Ulf Hellman, Christer Wernstedt, Carl-Hendrik Heldin
  • Substantially pure receptor like TGF-.beta. 1 binding molecules and uses thereof
    Patent number: 5229495
    Abstract: The invention relates to a family of substantially pure, receptor like TGF-.beta.1 binding glycoproteins. These molecules are characterized by molecular masses of 160 kd, 70-80 kd, and 30-40 kd as determined by SDS-PAGE, and the ability to bind the TGF-.beta.1 molecule. This family of molecules is useful in identifying and/or quantifying TGF-.beta.1 in a sample, as well as inhibiting its effect on cells.
    Type: Grant
    Filed: June 18, 1991
    Date of Patent: July 20, 1993
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Hidenori Ichijo, Kohei Miyazono, Lars Ronnstrand, Ulf Hellman, Christer Wernstedt, Carl-Henrik Heldin